Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
romiplostim + prednisone
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Nplate + prednisone is a combination regimen consisting of romiplostim (Nplate), a thrombopoietin (TPO) receptor agonist, and prednisone, a synthetic glucocorticoid corticosteroid. Romiplostim is a recombinant Fc-peptide fusion protein (peptibody) that binds to and activates the TPO receptor (c-Mpl) on megakaryocytes, stimulating intracellular signaling pathways (primarily JAK2/STAT5) to increase platelet production. Prednisone is a small-molecule glucocorticoid receptor agonist that, upon metabolic conversion to prednisolone, suppresses the immune system and reduces the autoimmune destruction of platelets. This combination is primarily investigated for the treatment of primary immune thrombocytopenia (ITP), particularly in newly diagnosed or previously untreated adult patients, to rapidly elevate platelet counts and achieve sustained remission while minimizing long-term corticosteroid exposure. Amgen is evaluating this combination in the Phase 3 ROMISTER trial.
- Other names
- Nplate + prednisoloneNplate + prednisoneromiplostim + prednisolone
02
Targets
GR (Glucocorticoid receptor)TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on romiplostim + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on romiplostim + prednisone.